FILING ANALYSIS · MONDAY, NOVEMBER 16
ENDRA Life Sciences Inc. NDRA — 8-K: Results of Operations and Financial Condition
negative
ENDRA Life Sciences reports a net loss of $1.5 million for the third quarter of 2026 and announces a proposed merger with Noble Africa, which includes a concurrent private placement expected to result in $50 million in gross proceeds, but the company's cash position is limited with only $1.5 million in unrestricted cash, and the transaction is subject to customary closing conditions, including sto
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →